# Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients

> **NCT03055286** · PHASE1,PHASE2 · TERMINATED · sponsor: **JW Pharmaceutical** · enrollment: 15 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** CWP232291

## Key facts

- **NCT ID:** NCT03055286
- **Lead sponsor:** JW Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-06
- **Primary completion:** 2025-08-26
- **Final completion:** 2025-08-26
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** business/strategic reason
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03055286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03055286, "Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03055286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*